Picture of Oxford Cannabinoid Technologies Holdings logo

OCTP Oxford Cannabinoid Technologies Holdings Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-22.02%
3m-55.92%
6m-57.21%
1yr-71.48%
Volume Change (%)
10d/3m+229.96%
Price vs... (%)
52w High-79.06%
50d MA-21.7%
200d MA-53.56%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-250.56%
Return on Equity-104.7%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Apr 202430th Apr 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Oxford Cannabinoid Technologies Holdings EPS forecast chart

Profile Summary

Oxford Cannabinoid Technologies Holdings plc is a United Kingdom-based pharmaceutical company developing prescription cannabinoid medicines. The Company is working with three types of cannabinoid compounds: synthesized phytocannabinoids, cannabinoid derivatives and novel chemical entities. Its drug development pipeline comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and other therapeutic areas. It has a portfolio of four drug development programs: Program 1 (OCT461201), Program 2 (OCT130401), Program 3 (Cannabinoid derivative) and Program 4 (Cannabinoid derivative). Its OCT461201 is a new chemical entity, CB2 receptor agonist, chemically synthesized to behave like a cannabinoid. Its OCT130401 is a drug/device combination. It has a portfolio of over 500 derivatives and intellectual property rights, including 14 patent families and associated research data.

Directors

    Last Annual
    April 30th, 2023
    Last Interim
    October 31st, 2023
    Incorporated
    February 4th, 2021
    Public Since
    May 21st, 2021
    No. of Employees
    7
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    gb flag iconLondon Stock Exchange
    Shares in Issue
    1,088,415,644
    Blurred out image of a map
    Address
    Prama House, 267 Banbury Road, OXFORD, OX2 7HT
    Web
    Phone
    +44 2030342820
    Auditors
    Moore Kingston Smith LL

    OCTP Share Price Performance

    Upcoming Events for OCTP

    Oxford Cannabinoid Technologies Holdings PLC Annual Shareholders Meeting

    Similar to OCTP

    Picture of 4Basebio logo

    4Basebio

    gb flag iconLondon Stock Exchange

    Picture of Allergy Therapeutics logo

    Allergy Therapeutics

    gb flag iconLondon Stock Exchange

    Picture of Arecor Therapeutics logo

    Arecor Therapeutics

    gb flag iconLondon Stock Exchange

    Picture of Avacta logo

    Avacta

    gb flag iconLondon Stock Exchange

    Picture of Batm Advanced Communications logo

    Batm Advanced Communications

    gb flag iconLondon Stock Exchange

    FAQ